At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
rHSA-GCSF 2.4mg +1 moredrug
Likely dose
rHSA-GCSF 2.4mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy and Safety Phase IIb Study of Recombinant Human Serum Albumin/ Granulocyte Colony-Stimulating Factor Fusion Protein for Injection to Prevent Neutrophilic Granulocytopenia Among Chemotherapy Breast Cancer Patients
In Brief
A Phase 2 clinical trial evaluating rHSA-GCSF 2.4mg and GCSF for Chemotherapy-induced Neutropenia. Completed, enrolled 80 participants across 1 site.
Detailed Summary
Evaluation of the efficacy and safety of recombinant human serum albumin / granulocyte-stimulating factor fusion protein for injection to prevent chemotherapy-induced neutropenia
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChemotherapy-induced Neutropenia
CountriesChina
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 2017
Enrollment StartOct 2017
Primary CompletionJul 2018
Study CompletionApr 2019
TodayJul 2026
First PostedAug 16, 2017
Enrollment StartOct 19, 2017
Primary CompletionJul 23, 2018
Study CompletionApr 24, 2019
TodayJul 1, 2026
Enrollment to primary: 9 monthsPosted 8.9 years ago
Interventions
rHSA-GCSF 2.4mgdrug
Human Serum Albumin GCSF 2.4mg at day 3 and day 7
GCSFdrug
GCSF 5 mcg/kg/day